|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Quantitative Lymphocyte Subsets: T, B, and Natural Killer (NK), Blood
Test Code94585
CPT Codes
86355, 86357, 86359, 86360
Preferred Specimen
3 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
1 mL
Instructions
1.) Date of draw is required.
2.) For serial monitoring, we recommend that specimen draws be performed at the same time of day.
Due to limited stability, specimens must be sent directly to the performing lab via overnight shipping/delivery. Specimens can only be sent Monday through Thursday.
2.) For serial monitoring, we recommend that specimen draws be performed at the same time of day.
Due to limited stability, specimens must be sent directly to the performing lab via overnight shipping/delivery. Specimens can only be sent Monday through Thursday.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: <52 hours
Refrigerated: Unacceptable
Frozen: Unacceptable
Refrigerated: Unacceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly lipemic • Other specimen in aliquot tubes
Methodology
Flow Cytometry
FDA Status
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Setup Schedule
Set up: Daily; Report available: 1-2 days
Reference Range
See Laboratory Report
Clinical Significance
Serial monitoring of CD4 T-cell count in HIV-positive patients
Follow-up and diagnostic evaluation of primary immunodeficiencies, including severe combined immunodeficiency
Immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, and other immunological conditions where such treatment is utilized
Assessment of immune reconstitution post hematopoietic cell transplantation
Early screening of gross quantitative anomalies in lymphocyte subsets in infection or malignancies
Absolute quantitation of circulating B cells for diagnosis of chronic lymphocytic leukemia patients as indicated in the 2008 International Workshop on Chronic Lymphocytic Leukemia guidelines
Follow-up and diagnostic evaluation of primary immunodeficiencies, including severe combined immunodeficiency
Immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, and other immunological conditions where such treatment is utilized
Assessment of immune reconstitution post hematopoietic cell transplantation
Early screening of gross quantitative anomalies in lymphocyte subsets in infection or malignancies
Absolute quantitation of circulating B cells for diagnosis of chronic lymphocytic leukemia patients as indicated in the 2008 International Workshop on Chronic Lymphocytic Leukemia guidelines
